Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Net Cash Flow (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Net Cash Flow for 2 consecutive years, with $8.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow rose 337.98% to $8.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $17.5 million, a 314.93% increase, with the full-year FY2025 number at $1.6 million, up 280.42% from a year prior.
  • Net Cash Flow was $8.3 million for Q4 2025 at Neuphoria Therapeutics, up from -$541033.0 in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $12.6 million in Q1 2025 to a low of -$4.7 million in Q3 2024.